AI summary by TwinMind

Natera ft. Matthew Rabinowitz - A Personal Mission That Led to a Biotech Revolution

Sequoia Capital

52m 55s

Company Overview & Personal Motivation

  • Natera: global leader in women's health, oncology, organ transplant rejection testing
  • 40% of US pregnancies tested using Natera technology
  • Nearly half of US oncologists have ordered Natera cancer screening tests
  • Founded by Matthew Rabinowitz (electrical engineering/physics background, Stanford top student, PhD)
  • Co-founded with Jonathan Sheena (2004, mobile startup background)

Genesis Story - Personal Tragedy Drives Innovation

  • 2003: Matthew's sister had baby with Down syndrome, died after 6 days
  • Hospital only discovered condition at birth despite being top facility
  • Matthew couldn't understand how 21st century technology hadn't reached diagnostics
  • Mission-driven from start: apply signal processing to genetics
  • 2009: Matthew lost second child to genetic condition, screening tests failed to detect
    • Used sample from that pregnancy for NIH grant submissions
    • Entirely emotional decision to pursue prenatal testing
    • "This just broke me... engineering me took over... problem I have to solve"

Early Technology Development - Spectrum Test

  • Initial focus: IVF pre-implantation testing market
  • Existing methods: crude, only tested 5 of 22 chromosomes
  • Natera's breakthrough: Bayesian optimization framework using parental DNA
  • Key insight: limit search space using mom/dad genetic data vs. universe of possibilities
  • Challenge: single cell analysis from embryo biopsy, extremely noisy data
  • Spectrum test: first to use probabilistic modeling of embryo genome from parents
  • 2009: Spectrum launched for public use

Early Struggles & Market Reality

  • IVF market limitations: ~150,000 cycles/year in US
  • Even full market penetration = ~$600M total addressable market
  • Early volumes: 100-105 tests/month in 2010
  • Board concerns when volume dropped to 90 tests
  • Steve Chapman (CEO) thought he might be fired after 3 months
  • Funding challenges: Silicon Valley skeptical of genetics, non-geneticists questioned
  • Mission-driven approach: "don't worry about funding when you have mission"

Pivot to Prenatal Testing - Panorama

  • Natural pregnancies: much larger market than IVF
  • Existing prenatal testing (from 1980s): 20% of genetic abnormalities missed
  • 19 out of 20 positive results were false positives
  • Panorama technology: cell-free fetal DNA from mother's blood at 9 weeks
  • Similar signal processing challenge: extract fetal DNA from maternal blood
  • Fourth to market (2013) behind Illumina, Roche, Sequenom
  • Competitors had 2-year head start, established sales teams

Competitive Challenges & Differentiation

  • Illumina acquired main competitor Verinata during Natera's fundraising
  • Matthew "curled up in fetal position literally shaking" over supplier/competitor conflict
  • Natera's advantages:
    • Could separate maternal, paternal, fetal DNA informatically
    • Detected microdeletions using deep learning neural networks
    • Better user experience (tracking, communication vs. "dark dingy draw stations")
  • Decision to offer test to all pregnancies vs. just high-risk (15% → 100% of market)

Rapid Growth & Scaling Challenges

  • July 2015: IPO
  • Processing over 1 million samples/year for Panorama alone
  • Massive hiring: "stacking engineers on top of each other"
  • Constant office expansion: "drinking from fire hose"
  • Steve Chapman: "literally stacking Engineers on top of each other"
  • Sarah Elliot: "onslaught of open positions, interviews, challenge finding top engineering talent"

Oncology Expansion Decision

  • Core technology applicable: cancer DNA sheds into bloodstream like fetal DNA
  • Massively multiplexed PCR protocol: all primers in single reaction
  • Personalized assays based on patient's specific tumor mutations
  • Capability: detect single cancer molecule in blood ("one blade of grass in 100,000 soccer fields")
  • Signatera test: cancer recurrence monitoring

Major Business Risk & Criticism

  • Women's Health not yet profitable when expanding to oncology
  • Burning cash, no full Panorama reimbursement
  • Stock dropped to $7/share, stayed there ~3 years
  • Investor criticism: "abandon oncology, focus on women's health"
  • Public investors "repeatedly called and implored" to abandon oncology
  • Some analysts/investors "got really frustrated" in meetings
  • Employee demoralization: "is the company going to make it?"

Perseverance & Mission Focus

  • Core team stayed mission-focused despite $7 stock price
  • Lost some employees but core believers remained
  • Unified vision across business units, strong collaboration
  • Resource constraints drove innovation: "how do we do it differently with fewer resources"
  • Matthew's philosophy: "bless the obstacle... put faith in science"

Current Success Metrics

  • 2024: ~$1.5B revenue projected
  • Stock price: $7 → over $100
  • Panorama: most widely used prenatal test in America
  • 55-60% of US women's health genetic testing market share
  • Oncology: ~50% of US oncologists using Signatera
  • Q1 2024: 100,000+ Signatera samples processed (vs. few thousand in 2019)
  • Reimbursement: bladder, colon, breast, ovarian cancers
  • 7-year cancer survivor example (Jonathan Sheena's mother)

Future Vision & AI Integration

  • Order of magnitude growth potential ahead
  • Large language models for clinical data curation
  • AI modeling for disease susceptibility
  • Maintain innovation pace to preserve market leadership
  • Mission walls: family photos from customers thanking Natera
  • Philosophy: "hard creates value and barriers to others"

TwinMind

Get summaries like this for your own meetings

TwinMind takes notes in the background during meetings, lectures, and calls, then writes the summary for you.

Free plan to get started

No bot joins your calls

Phone, desktop & Chrome apps

Your next meeting, summarized like this

TwinMind listens in the background and turns meetings, lectures, and calls into searchable notes you can chat with. Start free.

Available on phone, desktop & Chrome

Your next meeting, summarized like this

TwinMind listens in the background and turns meetings, lectures, and calls into searchable notes you can chat with. Start free.

Available on phone, desktop & Chrome

Your next meeting, summarized like this

TwinMind listens in the background and turns meetings, lectures, and calls into searchable notes you can chat with. Start free.

Available on phone, desktop & Chrome